NEXT-ERA DNA DAMAGE RESPONSE THERAPIES

Onco-Innovations is a Canadian preclinical-stage precision oncology compnay dedicated to cancer research and treatment currently leading the development of Polynucleotide Kinase Phosphatase (PNKP) inhibitors, a unique and emerging class of DNA Damage Response (DDR) therapies. By combining exclusively licensed drug candidates with advanced nanoparticle (NP) tumour delivery and an AI-native discovery platform, we aim to redefine the treatment of cancers resistant to traditional therapies with its lead drug candidate, ONC010: a nanoparticle-encapsulated PNKP inhibitor.